HAEM5:Systemic chronic active EBV disease: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Karin.Miller (talk | contribs) |
Karin.Miller (talk | contribs) |
||
| Line 169: | Line 169: | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
* The WHO 5<sup>th</sup> edition essential diagnostic criteria include:<ref name=":0" /> | * The WHO 5<sup>th</sup> edition essential diagnostic criteria include:<ref name=":0" /><ref name=":5">The WHO Classification of Tumours Editorial Board, ed. ''Haematolymphoid Tumours: Who Classification of Tumours''. 5th ed. International Agency for Research on Cancer; 2024.</ref> | ||
** Persistent (greater than 3 months) infectious mononucleosis-like symptoms | ** Persistent (greater than 3 months) infectious mononucleosis-like symptoms | ||
** Increased EBV DNA in the peripheral blood or EBER-positive cells in affected organs with evidence of EBV infection in T or NK-cells | ** Increased EBV DNA in the peripheral blood or EBER-positive cells in affected organs with evidence of EBV infection in T or NK-cells | ||
| Line 181: | Line 181: | ||
** Exclusion of known immunodeficiency, malignancy, or autoimmune disorders | ** Exclusion of known immunodeficiency, malignancy, or autoimmune disorders | ||
* '''Both the WHO 5<sup>th</sup> edition and ICC include detection of increased EBV DNA in the peripheral blood and/or EBV RNA (EBER) or viral protein in T or NK-cells of affected tissues.<ref name=":0" /><ref name=":1" />''' | * '''Both the WHO 5<sup>th</sup> edition and ICC include detection of increased EBV DNA in the peripheral blood and/or EBV RNA (EBER) or viral protein in T or NK-cells of affected tissues.'''<ref name=":5" />'''<ref name=":0" /><ref name=":1" />''' | ||
** Whole blood or peripheral blood mononuclear cells are preferred for EBV DNA PCR testing, as serum or plasma are less sensitive for CAEBV disease<ref>{{Cite journal|last=Kimura|first=Hiroshi|last2=Cohen|first2=Jeffrey I.|date=2017|title=Chronic Active Epstein-Barr Virus Disease|url=https://pubmed.ncbi.nlm.nih.gov/29375552|journal=Frontiers in Immunology|volume=8|pages=1867|doi=10.3389/fimmu.2017.01867|issn=1664-3224|pmc=5770746|pmid=29375552}}</ref> | ** Whole blood or peripheral blood mononuclear cells are preferred for EBV DNA PCR testing, as serum or plasma are less sensitive for CAEBV disease<ref>{{Cite journal|last=Kimura|first=Hiroshi|last2=Cohen|first2=Jeffrey I.|date=2017|title=Chronic Active Epstein-Barr Virus Disease|url=https://pubmed.ncbi.nlm.nih.gov/29375552|journal=Frontiers in Immunology|volume=8|pages=1867|doi=10.3389/fimmu.2017.01867|issn=1664-3224|pmc=5770746|pmid=29375552}}</ref> | ||
** In tissues, using a double stain for B, T, or NK-cell markers and EBV is recommended. | ** In tissues, using a double stain for B, T, or NK-cell markers and EBV is recommended. | ||